Cargando…

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis

PURPOSE: To assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis. METHODS: PubMed was searched for studies published until January 28, 2023, that investigated the clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Mingwei, Zhang, Yifan, Guo, Jianjun, Guo, Cuicui, Yang, Xue, Ma, Xue, Xu, Hao, Xiang, Shuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390296/ https://www.ncbi.nlm.nih.gov/pubmed/37529613 http://dx.doi.org/10.3389/fendo.2023.1188969

Ejemplares similares

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Associations of LRP5 Gene With Bone Mineral Density, Bone Turnover Markers, and Fractures in the Elderly With Osteoporosis
por: Wang, Qi-Fei, et al.
Publicado: (2020)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Undercarboxylated Osteocalcin and Its Associations With Bone Mineral Density, Bone Turnover Markers, and Prevalence of Osteopenia and Osteoporosis in Chinese Population: A Cross-Sectional Study
por: Xu, Yang, et al.
Publicado: (2022)

Perirenalfat thickness is associated with bone turnover markers and bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Wang, Wei, et al.
Publicado: (2022)

Evaluation of bone mineral density and bone turnover in children on anticoagulation
por: Thom, Katharina, et al.
Publicado: (2023)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Romosozumab for osteoporosis
Publicado: (2021)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Association Between Bone Mineral Density, Bone Turnover Markers, and Serum Cholesterol Levels in Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2018)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Effects of metformin on bone mineral density and bone turnover markers: a systematic review and meta-analysis
por: Hu, Jinhua, et al.
Publicado: (2023)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Romosozumab and Blosozumab: Alternative Drugs of Mechanical Strain-Related Stimulus Toward a Cure for Osteoporosis
por: Sugiyama, Toshihiro, et al.
Publicado: (2015)

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
por: Miyauchi, Akimitsu, et al.
Publicado: (2019)

Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study
por: Dito, Giorgia, et al.
Publicado: (2023)

Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis
por: Stumpf, U., et al.
Publicado: (2021)

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
por: Brunova, Jana, et al.
Publicado: (2018)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study
por: Inage, Kazuhide, et al.
Publicado: (2021)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment
por: Petranova, Tzvetanka, et al.
Publicado: (2014)

Associations of insulin resistance and insulin secretion with bone mineral density and osteoporosis in a general population
por: Fu, Yi-Hsiu, et al.
Publicado: (2022)

Association of selenium intake with bone mineral density and osteoporosis: the national health and nutrition examination survey
por: Peng, Shiyu, et al.
Publicado: (2023)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Associations of IDUA and PTCH1 with Bone Mineral Density, Bone Turnover Markers, and Fractures in Chinese Elderly Patients with Osteoporosis
por: Wang, Qifei, et al.
Publicado: (2019)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
por: Yamaguchi, Yuta, et al.
Publicado: (2020)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Bone turnover markers in serum but not in saliva correlate with bone mineral density
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2020)

Bone Turnover Markers and Bone Mineral Density in Children with Hypophosphatemic Rickets
por: Michałus, Izabela, et al.
Publicado: (2022)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report
por: Del Sindaco, Giulia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8647dkvgacu8dim2t2qbap8r3b